| HOME >> BIOLOGY >> TECHNOLOGY |
Acquisition and
divestiture-related
charges 667 0.44 4,566 3.58
Restructuring charges 131 0.09
Litigation-related charges 294 0.20
Amortization expense 560 0.37 421 0.32
Adjusted results $1,157 $0.77 (1) $1,410 $1.09 (2)
(1) Calculated by assuming stock-based dilution of 13.1 million shares
(2) Calculated by assuming stock-based dilution of 15.6 million shares
BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET (LOSS) INCOME AND NET (LOSS) INCOME PER SHARE
RECONCILIATIONS (CONT.)
(Unaudited)
Year Ended
December 31,
2007 2006
Acquisition and divestiture-related charges:
Loss on assets held for sale $560
Purchased research and development 85 $4,186
Integration costs (a) 29 61
Fair-value adjustment for the sharing
of proceeds feature of the Abbott
Laboratories stock purchase (b) 8 95
Step-up value of inventory sold (c) 267
CRM technology offering charge (c) 31
Charitable donation (b) 5
Business optimization charges (d) 19
AAA program cancellation net credit (e) (36)
682 4,628
Income tax benefit (g) (15)
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved |